Tourmaline Bio Inc. (TRML)
NASDAQ (NGS) NASDAQ (NGS) Primary NASDAQ (NGS) Summary
TRML Chart
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition
Pacibekitug showed statistically significant hs-CRP reduction in CKD patients in the phase 2 TRANQUILITY study, establishing proof-of-concept for IL-6 inhibition. Positive data supports advancing pacibekitug to a phase 3 cardiovascular outcomes trial for ASCVD, pending an FDA meeting in late 2025. The 7 major Atherosclerotic Cardiovascular Disease markets are expected to reach $30.6 billion by 2035.
Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting
Tourmaline Bio's Pacibekitug shows promise in treating thyroid eye disease, with pivotal phase 2b data expected in 2025 and a phase 3 study starting in 2024. The 7 major thyroid eye disease markets are expected to reach $4.13 billion by 2034. The company is also exploring Pacibekitug for atherosclerotic cardiovascular disease, with phase 2 TRANQUILITY study results anticipated in the first half of 2025.
Tourmaline Bio Inc. (TRML) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tourmaline Bio Inc. ever had a stock split?
Tourmaline Bio Inc. Profile
| - Industry | - Sector | Dr. Sandeep C. Kulkarni M.D. CEO | NASDAQ (NGS) Exchange | 89157D105 CUSIP |
| United States Country | 70 Employees | 20 Oct 2023 Last Dividend | 20 Oct 2023 Last Split | - IPO Date |
Overview
Tourmaline Bio, Inc. is distinguished as a clinical stage biotechnology entity committed to the development of breakthrough medications for individuals grappling with severe immune and inflammatory diseases. Transitioning from Tourmaline Bio, LLC to Tourmaline Bio, Inc. in September 2022, the company has swiftly made strides in its sector since its inception in 2021. Centralized in New York, New York, Tourmaline Bio, Inc. is at the forefront of revolutionizing treatment paradigms in its focused therapeutic areas, leveraging cutting-edge science and technology to address unmet medical needs.
Products and Services
- TOUR006:
- Development Pipeline for ASCVD and TED:
Primary in Tourmaline Bio's arsenal of innovative treatments, TOUR006 emerges as a pioneering human anti-IL-6 monoclonal antibody. This carefully engineered molecule is designed to selectively target and bind to interleukin-6 (IL-6), a critical proinflammatory cytokine implicated in the pathophysiology of numerous autoimmune and inflammatory conditions. By intervening at this juncture, TOUR006 holds the potential to ameliorate symptoms and alter the disease trajectory for patients suffering from conditions marked by excessive or dysregulated IL-6 signaling.
Tourmaline Bio is also extending its research and development efforts to encompass therapies for atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). Both areas represent significant quests for improved treatments due to their prevalence and the substantial impact on patient quality of life. The company's dedication to advancing the science and clinical management of these diseases underscores its broader mission to address a wide spectrum of immune and inflammatory diseases with novel therapeutic options.
